Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Nature Medicine

Volumn 13, Issue 7, 2007, Pages 843-850

  Darrah, Patricia A ^a   Patel, Dipti T ^a   De Luca, Paula M ^a   Lindsay, Ross W B ^a   Davey, Dylan F ^a   Flynn, Barbara J ^a   Hoff, Søren T ^b   Andersen, Peter ^b   Reed, Steven G ^c   Morris, Sheldon L ^d   Roederer, Mario ^e   Seder, Robert A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; LIVE VACCINE; RECOMBINANT LEISHMANIAL PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; PROTOZOAL VACCINE;

ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CORRELATION FUNCTION; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTECTION; PROTOZOAL INFECTION; TH1 CELL; ANIMAL; C57BL MOUSE; IMMUNOLOGY; SKIN LEISHMANIASIS;

LEISHMANIA MAJOR; MUS;

ANIMALS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED C57BL; PROTOZOAN VACCINES; TH1 CELLS;

EID: 34250303350     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1592     Document Type: Article

References (49)

1. Seder, R.A. & Hill, A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 406, 793-798 (2000).
2. Murphy, K.M. & Reiner, S.L. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2, 933-944 (2002).
3. Bucy, R.P. et al. Heterogeneity of single cell cytokine gene expression in clonal T cell populations. J. Exp. Med. 180, 1251-1262 (1994).
4. Openshaw, P. et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J. Exp. Med. 182, 1357-1367 (1995).
5. Roman, E. et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J. Exp. Med. 196, 957-968 (2002).
6. H1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3, 852-858 (2002).
7. Hayashi, N., Liu, D., Min, B., Ben-Sasson, S.Z. & Paul, W.E. Antigen challenge leads to in vivo activation and elimination of highly polarized TH1 memory T cells. Proc. Natl. Acad. Sci. USA 99, 6187-6191 (2002).
8. + T cells endowed with proliferative capacity. J. Exp. Med. 198, 1909-1922 (2003).
9. Reece, W.H. et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10, 406-410 (2004).
10. Cooper, A.M. et al. Disseminated tuberculosis in interferon λ gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993).
11. Flynn, J.L. et al. An essential role for interferon g in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254 (1993).
12. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179, 1367-1371 (1994).
13. Elias, D., Akuffo, H. & Britton, S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 99, 363-368 (2005).
14. Gicheru, M.M. et al. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69, 245-251 (2001).
15. Leal, I.S., Smedegard, B., Andersen, P. & Appelberg, R. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-γ generation. Immunology 104, 157-161 (2001).
16. Oliveira, M.R. et al. Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions. Parasitology 131, 477-488 (2005).
17. Blackwell, J.M. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 112(suppl.), S67-S74 (1996).
18. Bloom, B.R., Flynn, J., McDonough, K., Kress, Y. & Chan, J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 191, 526-536 (1994).
19. Bogdan, C., Moll, H., Solbach, W. & Rollinghoff, M. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur. J. Immunol. 20, 1131-1135 (1990).
20. Liew, F.Y., Li, Y. & Millott, S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145, 4306-4310 (1990).
21. Perfetto, S.P., Chattopadhyay, P.K. & Roederer, M. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4, 648-655 (2004).
22. Scott, P. Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol. Res. 27, 489-498 (2003).
23. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
24. Uzonna, J.E., Wei, G., Yurkowski, D. & Bretscher, P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167, 6967-6974 (2001).
25. Modabber, F. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(suppl 1), 83-88 (1995).
26. + T cell responses and protection against Leishmania major infection. J. Exp. Med. 195, 1565-1573 (2002).
27. von Stebut, E. et al. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-γ- independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA. J. Invest. Dermatol. 119, 621-628 (2002).
28. Barouch, D.H. Rational design of gene-based vaccines. J. Pathol. 208, 283-289 (2006).
29. Tatsis, N. & Ertl, H.C. Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629 (2004).
30. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
31. Heppner, D.G., Jr et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23, 2243-2250 (2005).
32. Wang, J. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357-6365 (2004).
33. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
34. Andersen, P. & Doherty, T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3, 656-662 (2005).
35. Zaph, C., Uzonna, J., Beverley, S.M. & Scott, P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10, 1104-1110 (2004).
36. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
37. + T cell responses: the alternative approaches. Annu. Rev. Immunol. 15, 297-322 (1997).
38. Jelley-Gibbs, D.M. et al. Repeated stimulation of CD4 effector T cells can limit their protective function. J. Exp. Med. 201, 1101-1112 (2005).
39. Iezzi, G., Karjalainen, K. & Lanzavecchia, A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8, 89-95 (1998).
40. Jelley-Gibbs, D.M. et al. Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J. Exp. Med. 202, 697-706 (2005).
41. Steinman, R.M. & Hemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
42. O'Garra, A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275-283 (1998).
43. + T cells upon acute versus persistent viral infection. Immunity 9, 449-457 (1998).
44. Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249-1258 (2006).
45. Sacks, D. & Sher, A. Evasion of innate immunity by parasitic protozoa. Nat. Immunol. 3, 1041-1047 (2002).
46. + T cells. Blood 107, 4781-4789 (2006).
47. Skeiky, Y.A. et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20, 3292-3303 (2002).
48. Belkaid, Y. et al. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165, 969-977 (2000).
49. Perfetto, S.P. et al. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 313, 199-208 (2006).